tiprankstipranks
Intelligent Bio Solutions (INBS)
NASDAQ:INBS
US Market

Intelligent Bio Solutions (INBS) AI Stock Analysis

Compare
250 Followers

Top Page

IN

Intelligent Bio Solutions

(NASDAQ:INBS)

60Neutral
INBS shows strong growth potential through strategic expansion and partnerships, particularly its planned entry into the U.S. market. However, challenges with negative profitability and cash flow, along with a negative P/E ratio, weigh on the overall score. Positive technical indicators provide some support, but financial performance remains a key concern.

Intelligent Bio Solutions (INBS) vs. S&P 500 (SPY)

Intelligent Bio Solutions Business Overview & Revenue Model

Company DescriptionIntelligent Bio Solutions (INBS) is a company focused on developing and commercializing innovative biological solutions that address critical needs within the biotechnology and healthcare sectors. The company specializes in creating advanced diagnostic tools and therapeutic platforms that leverage cutting-edge technology and biological research. These products are designed to enhance patient care and improve health outcomes by providing more accurate and timely diagnostic information.
How the Company Makes MoneyIntelligent Bio Solutions makes money through the sale of its diagnostic tools and therapeutic platforms to healthcare providers, research institutions, and other entities within the biotech industry. The company generates revenue through direct product sales, licensing agreements, and collaborations with strategic partners. These partnerships may include research and development collaborations where INBS receives funding or milestone payments in exchange for access to its proprietary technology. Additionally, the company may engage in service contracts where it provides specialized testing or research services to its clients.

Intelligent Bio Solutions Financial Statement Overview

Summary
INBS is experiencing revenue growth and improvement in gross profit, but it faces challenges due to persistent negative earnings and cash flow. The balance sheet is stable with manageable debt, but the company must improve profitability and cash generation.
Income Statement
55
Neutral
INBS has shown a significant improvement in revenue over the past years, with a notable increase in gross profit margin compared to previous periods. However, the company is still struggling with negative EBIT and net income, leading to negative profit margins. The revenue growth is promising, yet profitability remains a key challenge.
Balance Sheet
60
Neutral
The company's balance sheet shows a moderate debt-to-equity ratio and a positive equity position, indicating some stability. Stockholders' equity has improved, providing a cushion for liabilities. However, the company needs to address its significant liabilities to improve financial health further.
Cash Flow
50
Neutral
INBS has a negative operating cash flow, which raises concerns about its ability to generate cash from operations. The free cash flow is also negative, although there has been a recent influx of financing cash flow. The company needs to improve cash generation to ensure long-term sustainability.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
3.03M3.11M1.26M0.001.98M188.74K
Gross Profit
1.25M1.43M326.67K0.001.98M188.74K
EBIT
-10.84M-10.28M-12.60M-8.34M-5.57M-2.71M
EBITDA
-10.10M-8.81M-9.47M30.82K-1.82M-561.19K
Net Income Common Stockholders
-10.69M-10.16M-10.63M-8.31M-7.04M-3.16M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.12M6.30M1.54M8.24M12.57M427.27K
Total Assets
8.83M13.78M10.35M12.35M20.40M2.48M
Total Debt
1.08M871.44K1.34M0.000.005.13M
Net Debt
-38.04K-5.43M-201.56K-8.24M-12.57M4.71M
Total Liabilities
5.67M5.60M6.67M5.81M6.85M7.69M
Stockholders Equity
3.28M8.33M3.80M6.62M13.61M-5.19M
Cash FlowFree Cash Flow
-7.82M-9.79M-7.88M-3.74M-11.30M-498.62K
Operating Cash Flow
-10.12M-9.57M-7.38M-3.36M-11.30M-498.62K
Investing Cash Flow
-176.24K-221.43K-694.14K-880.22K0.00-14.00K
Financing Cash Flow
11.50M14.56M1.44M0.0023.40M733.86K

Intelligent Bio Solutions Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.20
Price Trends
50DMA
1.82
Positive
100DMA
1.68
Positive
200DMA
1.68
Positive
Market Momentum
MACD
0.10
Positive
RSI
53.66
Neutral
STOCH
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBS, the sentiment is Positive. The current price of 2.2 is below the 20-day moving average (MA) of 2.25, above the 50-day MA of 1.82, and above the 200-day MA of 1.68, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 53.66 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBS.

Intelligent Bio Solutions Risk Analysis

Intelligent Bio Solutions disclosed 63 risk factors in its most recent earnings report. Intelligent Bio Solutions reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Intelligent Bio Solutions Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$18.93B-19.42%56.75%59.77%
68
Neutral
$1.02B18.0919.46%19.07%
60
Neutral
$14.78M-279.80%23.21%57.43%
53
Neutral
$8.52B-37.09%10.37%-389.98%
49
Neutral
$13.39B-30.11%-2.93%-4.69%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
46
Neutral
$2.52B-50.74%-7.03%-20233.78%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INBS
Intelligent Bio Solutions
2.20
-2.28
-50.89%
EXAS
Exact Sciences
46.35
-12.18
-20.81%
ILMN
Illumina
84.20
-40.29
-32.36%
QDEL
QuidelOrtho
36.87
-10.61
-22.35%
CDNA
CareDx
18.92
8.95
89.77%
NTRA
Natera
144.50
56.79
64.75%

Intelligent Bio Solutions Corporate Events

Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Intelligent Bio Solutions Plans U.S. Market Entry in 2025
Positive
Feb 10, 2025

On February 10, 2025, Intelligent Bio Solutions Inc. announced its 2024 growth achievements and its strategic plan to enter the U.S. market in 2025. In 2024, the company achieved significant revenue growth of 148% year-over-year, driven by the strong adoption of its drug screening technology. The company completed its FDA 510(k) pre-market notification in December, positioning itself to enter the U.S. drug screening market, which represents a large portion of the global demand. Rising drug positivity rates and increased safety regulations underscore the need for the company’s non-invasive testing solutions. The company anticipates continued growth, focusing on safety-critical industries and leveraging its expanding global customer base.

Product-Related AnnouncementsBusiness Operations and Strategy
Intelligent Bio Solutions Partners with Avon Freight Group
Positive
Feb 7, 2025

On February 7, 2025, Intelligent Bio Solutions announced that Avon Freight Group has adopted its non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing at its UK sites. This move by Avon, a significant logistics firm, highlights a shift towards more respectful and efficient drug testing methods, boosting workplace safety and culture. This partnership expands INBS’s network to over 400 accounts in 19 countries, reinforcing its industry leadership as the UK drug testing market is projected to reach $453 million by 2030. The company’s strategic growth, including a planned U.S. expansion following an FDA submission, positions it to address growing demand for scalable and cost-effective drug testing solutions.

Product-Related AnnouncementsBusiness Operations and Strategy
Intelligent Bio Solutions Expands Fingerprinting System Globally
Positive
Jan 31, 2025

On January 31, 2025, Intelligent Bio Solutions announced plans to upgrade its Intelligent Fingerprinting Drug Screening System with multilingual capabilities, enhancing accessibility for over 4 billion users globally. This strategic move supports the company’s international expansion and aligns with its 2025 entry into the US market, tapping into the growing demand for workplace drug testing solutions projected to reach $8 billion by 2030.

Product-Related AnnouncementsBusiness Operations and Strategy
Intelligent Bio Solutions Expands with UK Partnership
Positive
Jan 29, 2025

On January 29, 2025, Intelligent Bio Solutions Inc. announced that Quantum Traffic Management, a UK-based traffic management provider, adopted their Intelligent Fingerprinting Drug Testing Solution across ten sites to enhance workplace testing efficiency and safety. This transition from traditional saliva and urine testing to INBS’s rapid, non-invasive system marks a significant operational improvement for Quantum TM, and underscores INBS’s growing influence in the drug screening market, with over 400 accounts globally and plans to enter the US market in 2025.

Product-Related AnnouncementsBusiness Operations and Strategy
Intelligent Bio Solutions Partners with IVY Diagnostics
Positive
Jan 28, 2025

On January 28, 2025, Intelligent Bio Solutions announced a significant partnership with IVY Diagnostics to expand its Intelligent Fingerprinting Drug Testing Solution in Europe and the Middle East. This collaboration is strategic due to the projected growth of the drug screening market in these regions, with Europe expected to reach $3.6 billion by 2030. IVY Diagnostics, leveraging its extensive network and expertise, will help INBS capture new opportunities, particularly in drug rehabilitation and law enforcement, with ongoing trials in Italy. This partnership positions the company to effectively meet the rising demand for efficient drug screening solutions.

Product-Related AnnouncementsRegulatory Filings and Compliance
Intelligent Bio Solutions Submits FDA Premarket Notification
Positive
Dec 18, 2024

Intelligent Bio Solutions Inc. has submitted a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, a non-invasive and rapid drug testing method. This submission marks a significant step toward entering the US market, offering opportunities for growth and establishing the company as a leader in non-invasive testing solutions across various industries.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.